Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arzoxifene vs. Raloxifene in postmenopausal osteoporosis
NCT00383422Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2006
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of arzoxifene in osteoporosis (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent change in Lumbar Spine Bone Mineral Density at 12 months. Started Oct 2006; status: completed.
02
Drugs
arzoxifene
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00383422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383422.